Completed PHASE1 INTERVENTIONAL NCT00201812

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Sponsor: Immunex Corporation

Conditions Tumors

Interventions Dexamethasone Docetaxel Etanercept

Updated 6 times since 2017 Last updated: Dec 4, 2017 Started: Nov 30, 2000 Primary completion: Jan 31, 2004 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00201812, this PHASE1 trial focuses on Tumors and remains completed. Sponsored by Immunex Corporation, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immunex Corporation
Ohio State University Comprehensive Cancer Center

Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States